The Investor
24 Jul 2025, 09:36
Boston Scientific Reports Strong Q2 2025 Results; Raises Guidance
Boston Scientific posted Q2 2025 net sales of $5.06 billion, a 22.8% year-over-year increase, surpassing guidance. GAAP net income rose to $797 million ($0.53/share) from $324 million a year ago, with adjusted EPS at $0.75, also exceeding expectations.
Highlights:
• Cardiovascular segment drove growth with 23.2% organic increase.
• U.S. sales surged 30.7%, while APAC rose 18%.
• Key approvals included FDA expansion for FARAPULSE™ and CE mark for WATCHMAN FLX™ Pro.
• Company completed acquisitions of Intera Oncology and SoniVie Ltd. to enhance its oncology and hypertension portfolios.
CEO Mike Mahoney credited the global team for strong performance and affirmed long-term growth momentum.
Boston Scientific posted Q2 2025 net sales of $5.06 billion, a 22.8% year-over-year increase, surpassing guidance. GAAP net income rose to $797 million ($0.53/share) from $324 million a year ago, with adjusted EPS at $0.75, also exceeding expectations.
Highlights:
• Cardiovascular segment drove growth with 23.2% organic increase.
• U.S. sales surged 30.7%, while APAC rose 18%.
• Key approvals included FDA expansion for FARAPULSE™ and CE mark for WATCHMAN FLX™ Pro.
• Company completed acquisitions of Intera Oncology and SoniVie Ltd. to enhance its oncology and hypertension portfolios.
CEO Mike Mahoney credited the global team for strong performance and affirmed long-term growth momentum.
